Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Vertex Resolves To Reverse English Funding Rejection For CRISPR Sickle Cell Gene Therapy

Mar 15 2024

• By Neena Brizmohun

3d graphic of sickled blood cell — Casgevy is a one-off gene therapy for sickle cell disease • Source: Shutterstock

Related Content

UK Authorizes Vertex’s Casgevy, The World’s First CRISPR/Cas9 Gene Therapy

Nov 17 2023

Additional Topics

United Kingdom Europe France Cost Effectiveness Gene Therapy Health Technology Assessment Policy Reimbursement Pricing Strategies Pricing Debate Blood & Coagulation Disorders BioPharmaceutical

More from United Kingdom

More from Europe

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.